^
BIOMARKER:

PD-L1 underexpression

i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Entrez ID:
Related biomarkers:
PD-L1 underexpression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive: C1 - Off-label
Thorac Cancer - 2 weeks
PD-L1 underexpression
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: C3 – Early Trials
Thorac Cancer - 2 weeks
PD-L1 underexpression
Melanoma
ipilimumab
Sensitive: A1 - Approval
PD-L1 underexpression
Melanoma
nivolumab + ipilimumab
Sensitive: A1 - Approval
PD-L1 underexpression
NSCLC
nivolumab + ipilimumab
Sensitive: A2 - Guideline
PD-L1 underexpression
LUAD
nivolumab + ipilimumab
Sensitive: A2 - Guideline
PD-L1 underexpression
NSCLC
nivolumab
Resistant: B - Late Trials
PD-L1 underexpression
NSCLC
durvalumab + CP-675206
Sensitive: B - Late Trials
PD-L1 underexpression
NSCLC
pembrolizumab
Sensitive: C2 – Inclusion Criteria
PD-L1 underexpression
NSCLC
camrelizumab
Sensitive: C3 – Early Trials
PD-L1 underexpression
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 underexpression
NSCLC
ipilimumab + cemiplimab
Sensitive: C3 – Early Trials
PD-L1 underexpression
Urothelial Cancer
nivolumab + IPI-549
Sensitive: C3 – Early Trials
PD-L1 underexpression
Mantle Cell Lymphoma
ibrutinib
Resistant: C3 – Early Trials
PD-L1 underexpression
Cutaneous T-cell Lymphoma
durvalumab + lenalidomide
Sensitive: C3 – Early Trials
PD-L1 underexpression
Triple Negative Breast Cancer
atezolizumab + RG6180
Sensitive: C3 – Early Trials
PD-L1 underexpression
AML
XmAb14045
Sensitive: C3 – Early Trials
PD-L1 underexpression
Malignant Pleural Mesothelioma
PD1 inhibitor
Resistant: C3 – Early Trials
PD-L1 underexpression
SCCHN
cetuximab sarotalocan
Sensitive: C3 – Early Trials
PD-L1 underexpression
NSCLC
avelumab + VX15
Sensitive: C3 – Early Trials
PD-L1 underexpression
Gastric Adenocarcinoma
toripalimab + surufatinib
Sensitive: C3 – Early Trials
PD-L1 underexpression
Esophageal Squamous Cell Carcinoma
toripalimab + surufatinib
Sensitive: C3 – Early Trials
PD-L1 underexpression
CRC
atezolizumab + RG6180
Sensitive: C3 – Early Trials
PD-L1 underexpression
Melanoma
atezolizumab + RG6180
Sensitive: C3 – Early Trials
PD-L1 underexpression
NSCLC
atezolizumab + RG6180
Sensitive: C3 – Early Trials
PD-L1 underexpression
NSCLC
durvalumab
Resistant: C3 – Early Trials
PD-L1 underexpression
RCC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
PD-L1 underexpression
NSCLC
Immunotherapy
Resistant: C3 – Early Trials
PD-L1 underexpression
HCC
nivolumab
Sensitive: C3 – Early Trials